Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 5/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15874397 | 0.92 | CYP3A4 (0.42) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL1919346 | 0.91 | CYP3A4 (0.45) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL18028920 | 0.91 | CYP3A4 (0.43) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL1918078 | 0.91 | CYP3A4 (0.46) | CYP3A4CYP2C8KCNH2 | |
| SCHEMBL17099998 | 0.89 | CYP3A4 (0.41) | CYP3A4CYP2C8KCNH2 | |
| SCHEMBL15874359 | 0.89 | CYP3A4 (0.39) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL17099992 | 0.89 | CYP3A4 (0.43) | CYP3A4CYP2C8KCNH2 | |
| SCHEMBL1917811 | 0.87 | CYP3A4 (0.42) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL1917729 | 0.86 | CYP3A4 (0.43) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL1919864 | 0.85 | CYP3A4 (0.52) | CYP3A4CYP2C8KCNH2NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3119786-B1 | 6H-FURO[2,3-E]INDOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9914739-B2 | 6H-furo[2,3-E]indole compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-20170174696-A1 | 6H-FURO[2,3-E]INDOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3119786-A1 | 6H-FURO[2,3-E]INDOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-25 | — | — | EP | disclosed |
| WO-2015143257-A1 | 6H-FURO[2,3-E]INDOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174696-A1 | 6H-FURO[2,3-E]INDOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | IDO1, IDO2, HCCS | CYP3A4 69/4885CYP2C8 93/4885KCNH2 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.